04:44 PM EDT, 10/17/2025 (MT Newswires) -- Amgen ( AMGN ) and AstraZeneca ( AZN ) said late Friday the US Food and Drug Administration has approved Tezspire for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps in adult and pediatric patients aged 12 years and older.

The approval broadens the drug indication to a second disease characterized by epithelial-driven inflammation, they said.

The approval was based on efficacy and safety data from the late-stage WAYPOINT trial, the companies said, adding that regulatory applications are under review in Europe, China, Japan and several other countries.